PREPARATION OF SUSTAINED-RELEASE TIABROFENIC ACID BEADS

Yıl 2001, Cilt: 34 Sayı: 2, 0 - , 08.09.2015

A. Yildiz, D. Sensoy, A. Baytokova, Y. Ozsoy, A. Araman

Öz

Tiaprofenic acid (TA), has analgesic, anti-inflammatory and antipyretic
properties; it is an inhibitor of prostaglandin synthetase. The usual oral dose by
mouth is 600 mg daily; this may be given in 2 or 3 divided doses or once daily as a sustained-release preparation. TA is readily absorbed from the gastrointestinal tract. It has a short half-life of about 2 hours.
Sodium alginate is a natural, biodegradable and biocornpatible polymer used
as suspending and gelling agent in pharmaceutical technology. Recently, the alginate gel beads has received much attention in sustained-release preparation.
The aim of the present study was to formulate sustained-release TA beads
based on sodium alginate in order to reduce daily dose and to minimize gastrointestinal disturbance caused by the drug.
Key words: Tiaprofenic acid, sustained-release beads, sodium alginate.

Anahtar Kelimeler

-

PREPARATION OF SUSTAINED-RELEASE TIABROFENIC ACID BEADS

Öz

Tiaprofenic acid (TA), has analgesic, anti-inflammatory and antipyretic
properties; it is an inhibitor of prostaglandin synthetase. The usual oral dose by
mouth is 600 mg daily; this may be given in 2 or 3 divided doses or once daily as a
sustained-release preparation. TA is readily absorbed from the gastrointestinal tract.
It has a short half-life of about 2 hours.
Sodium alginate is a natural, biodegradable and biocornpatible polymer used
as suspending and gelling agent in pharmaceutical technology. Recently, the alginate
gel beads has received much attention in sustained-release preparation.
The aim of the present study was to formulate sustained-release TA beads
based on sodium alginate in order to reduce daily dose and to minimize gastrointestinal disturbance caused by the drug.

Anahtar Kelimeler

Tiaprofenic acid, sustained-release beads, sodium alginate.

Kaynakça

• 1. Martindale, The Extra Pharmacopoeia, 31 th Ed., p. 100, Royal Pharmaceutical Society, London, (1996)
• 2. Aydin, Z., Akbuga, J., Int. J. Pharm., 137, 133-136 (1996).
• 3. Munjeri, O., Collett, J.H., Fell, J.T., J. Control. Release 46, 273-278 (1997).
• 4. Wan, L.S.C., Lim, L.Y., Soh, B.L., S.T.P.Pharm., 4, 195-200 (1994).
• 5. Sezer, A.D., Akbuga, J., J. Microencapsul., 16, 195-203 (1999).
• 6. Sezer, A.D., Akbuga, J., J. Microerrcapsul., 16,687-696 (1999).
• 7. Santucci;F., Alhaique, Carafa, T., Coviello, T., Murtas, E., Riccieri, EM., J. Control. Release 42, 157-164 (1996).
• 8. Ozsoy, Y., Bergigadi, N., Boll. Cfzim. Farnr., 139, 120-123 (2000).
• 9. Wade, A., Weller, J., Handbook of Pharmaceutical Excipients, 2nd Ed., The American Pharmaceutical Association, p.10, Washington D.C., USA, 1994.
• 10. Rajaonarivony, M., Vauthier, C., Couarraze, G., Puisieux, F., Couvreur, P., J. Plrarnz. Sci., 82,912 (1993).
• 11. Tateshita, K., Sugawara, S., Imai, T., Otagiri, M., Biol. Pharm. Bull., 16,420-424 (1993).
• 12. Tiirkoglu, M., Giirsoy, A., Eroglu, L., Okar, Y., S.T.P. Pllarnr., 7, 135-140 (1997).
• 13. Kikuchi, A., Kawabuchi, M., Sugihara, M., Sakurai, Y., Okano, T., J. Control. Release, 47, 21-29 (1997).
• 14. Takka, S., Acartiirk, F., Phartnazie, 54, 137-139 (1999).
• 15. Imai, T., Kawasaki, C., Nishiyama, T., Otagari, M., Pharmazie 55,3218-222 (2000).
• 16. Higuchi, T., J. Pharm. Sci., 52, 1145-1149 (1963).
• 17. The United States Pharmacopeia XXLII, p.1791, United States Pharmacopeial Convention, Inc., (1995).